SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) recently ticked higher on strong volume. About 1456845 contracts were traded on 14-Mar-19 compared to daily average volume of 413820 shares. The first sale was made at $1.28 but later the stock became weaker, and closed with a gain of 6.98%. It was last traded at $1.38 apiece.

SELLAS Life Sciences Group, Inc. (SLS): Buy Candidate With 552.17% Upside Potential

SELLAS Life Sciences Group, Inc. is maintained at an average buy rating by 2 stock analysts, and there are at least 12.45% of shares outstanding that are currently legally short sold. The shares went down by -5.48% in value last month. Year-to-date it jumped 12.2%. Analysts are turning out to be more optimistic than before, with 2 of analysts who cover SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) advice adding it to buy candidate list. Wall Street experts also assign a $9 price target on SELLAS Life Sciences Group, Inc., pointing towards a 552.17% rally from current levels. The stock is trading for about -87.56% less than its 52-week high.

SLS Adds 3.76% In A Week

This company shares (SLS) so far managed to recover 72.48% since collapsing to its 52-week low. Over a week, it has seen its stock price volatility to stay at 6.06% while widening the period to a month, volatility was 5.19%. The share price has already crossed its 20 days moving average, floating at a distance of 0.77% and sits -4.16% lower versus its 50 days moving average. When looking at the past five sessions, the stock returned 3.76% gains and is down by -26.85% compared with its 200-day moving average of $1.4377. Also, SELLAS Life Sciences Group, Inc. (SLS) needs to overturn a -73.66% decrease it experienced over the past twelve months.

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) Consensus Call At 0

As regular trading ended, ContraVir Pharmaceuticals, Inc. (CTRV) stock brought in a -$0.03 drop to $0.24. The day started at a price of $0.2684 but then traded as high as $0.2684 before giving part of the gains back. As for this week, analysts appear content to stick with their bright outlook with the consensus call at 0. ContraVir Pharmaceuticals, Inc. is given 0 buy-equivalent recommendations, 0 sells and 0 holds. The company shares sank -90.77% from their peak of $2.6 and now has a $3.93 million market value of equity.

ContraVir Pharmaceuticals, Inc. (CTRV) Returns -14.89% This Year

The company had seen its current volume reaching at 274898 shares in the last trade. That compares with the recent volume average of 376060. At the close of regular trading, its last week’s stock price volatility was 14.05% which for the month reaches 16.11%. ContraVir Pharmaceuticals, Inc. dipped to as low as $0.22 throughout the day and has returned -14.89% in this year. At one point in the past year, the shares traded as low as $0.21 but has recovered 12.78% since then. [T4]